Perry RJ, Tamborska A, Singh B, et al. - According to this multicenter cohort study, in the context of vaccine-induced immune thrombotic thrombocytopenia (VITT), cerebral venous thrombosis is more severe. VITT-associated cerebral venous thrombosis may benefit from non-heparin anticoagulants and immunoglobulin therapy. Because previous diagnostic criteria omitted several patients with otherwise typical VITT-associated cerebral venous thrombosis, new diagnostic criteria that are more appropriate were proposed.

• The authors collected data on 99 patients from colleagues in 43 hospitals across the UK between April 1 and May 20, 2021.

• Patients with VITT-associated cerebral venous thrombosis had more thrombosed intracranial veins and were more likely to have extracranial thrombosis than non-VITT patients.

• When compared with the non-VITT control group, patients with VITT-associated cerebral venous thrombosis had a higher rate of mortality or dependence as the primary outcome.

• Patients with VITT who got non-heparin anticoagulants vs those who did not, and those who received intravenous immunoglobulin vs those who did not, had a lower risk of this adverse event.